Association of the First Antipsychotic Treatment Duration With the Re-Initiation of Treatment in Schizophrenia: A National Health Insurance Data-Based Study
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Objectives: The optimal duration of maintenance treatment for patients with first-episode schizophrenia (FES) remains unclear. We examined the first antipsychotic treatment duration and its association with re-initiation of treatment using a nationwide claim database. Methods: Data from the Health Insurance Review and Assessment Service database in South Korea for 2007–2016 were used. Linear regression analysis and Cox proportional hazard models were used to evaluate the associations between the duration of the first antipsychotic treatment, time to re-initiation of treatment, and occurrence of treatment re-initiation. Results: Of 30,143 patients with FES, 80.4% (n=24,231) received <2 years of the first antipsychotic treatment. In patients who discontinued treatment (n=23,030), the rate of treatment re-initiation was 74.2% (n=17,086). As the duration of the first antipsychotic treatment increased, the time to re-initiation of treatment decreased (β=-0.146, p<0.001); however, the rate of treatment reinitiation was relatively constant (hazard ratio=1.001, p<0.001). Conclusion: Long-term antipsychotic treatment was not significantly associated with the rate of treatment re-initiation but showed a negative association with the time to re-initiation of treatment. Further research is needed to better understand the optimal treatment duration for FES.
Abstract
Objectives: The optimal duration of maintenance treatment for patients with first-episode schizophrenia (FES) remains unclear. We examined the first antipsychotic treatment duration and its association with re-initiation of treatment using a nationwide claim database. Methods: Data from the Health Insurance Review and Assessment Service database in South Korea for 2007–2016 were used. Linear regression analysis and Cox proportional hazard models were used to evaluate the associations between the duration of the first antipsychotic treatment, time to re-initiation of treatment, and occurrence of treatment re-initiation. Results: Of 30,143 patients with FES, 80.4% (n=24,231) received <2 years of the first antipsychotic treatment. In patients who discontinued treatment (n=23,030), the rate of treatment re-initiation was 74.2% (n=17,086). As the duration of the first antipsychotic treatment increased, the time to re-initiation of treatment decreased (β=-0.146, p<0.001); however, the rate of treatment reinitiation was relatively constant (hazard ratio=1.001, p<0.001). Conclusion: Long-term antipsychotic treatment was not significantly associated with the rate of treatment re-initiation but showed a negative association with the time to re-initiation of treatment. Further research is needed to better understand the optimal treatment duration for FES.
참고문헌 (30)
- McGrath J, "Schizophrenia: a concise overview of incidence, prevalence, and mortality", Epidemiol Rev, 30, pp.67~76 (2008)
- Robinson D, "Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder", Arch Gen Psychiatry, 56, pp.241~247 (1999)
- Gitlin M, "Clinical outcome following neuroleptic discontinuation in patients with remitted recent-onset schizophrenia", Am J Psychiatry, 158, pp.1835~1842 (2001)
- Boonstra G, "Antipsychotic prophylaxis is needed after remission from a first psychotic episode in schizophrenia patients : results from an aborted randomised trial", Int J Psychiatry Clin Pract, 15, pp.128~134 (2011)
- Gaebel W, "Relapse prevention in first-episode schizophrenia : maintenance vs intermittent drug treatment with prodromebased early intervention : results of a randomized controlled trial within the German Research Network on Schizophrenia", J Clin Psychiatry, 72, pp.205~218 (2011)
- Emsley R, "Symptom recurrence following intermittent treatment in first-episode schizophrenia successfully treated for 2 years : a 3-year open-label clinical study", J Clin Psychiatry, 73, pp.e541~e547 (2012)
- McCreadie RG, "The Scottish first episode schizophrenia study:VII. two-year follow-up", Acta Psychiatr Scand, 80, pp.597~602 (1989)
- Kane JM, "Treatment strategies to prevent relapse and encourage remission", J Clin Psychiatry, 68(Suppl 14), pp.27~30 (2007)
- Wyatt RJ, "Research in schizophrenia and the discontinuation of antipsychotic medications", Schizophr Bull, 23, pp.3~9 (1997)
- Lieberman JA, "Psychobiologic correlates of treatment response in schizophrenia", Neuropsychopharmacology, 14, pp.13S~21S (1996)
- Alvarez-Jimenez M, "Risk factors for relapse following treatment for first episode psychosis : a systematic review and meta-analysis of longitudinal studies", Schizophr Res, 139, pp.116~128 (2012)
- De Hert M, "The use of continuous treatment versus placebo or intermittent treatment strategies in stabilized patients with schizophrenia : a systematic review and meta-analysis of randomized controlled trials with first-and second-generation antipsychotics", CNS Drugs, 29, pp.637~658 (2015)
- Leucht S, "Antipsychotic drugs versus placebo for relapse prevention in schizophrenia : a systematic review and meta-analysis", Lancet, 379, pp.2063~2071 (2012)
- Takeuchi H, "One-year symptom trajectories in patients with stable schizophrenia maintained on antipsychotics versus placebo : meta-analysis", Br J Psychiatry, 211, pp.137~143 (2017)
- Hui CLM, "Long-term effects of discontinuation from antipsychotic maintenance following first-episode schizophrenia and related disorders: a 10 year follow-up of a randomised, double-blind trial", Lancet Psychiatry, 5, pp.432~442 (2018)
- Sampson S, "Intermittent drug techniques for schizophrenia", Cochrane Database Syst Rev, pp.CD006196~ (2013)
- Newcomer JW, "Metabolic considerations in the use of antipsychotic medications : a review of recent evidence", J Clin Psychiatry, 68(Suppl 1), pp.20~27 (2007)
- Bostwick JR, "Antipsychotic-induced hyperprolactinemia", Pharmacotherapy, 29, pp.64~73 (2009)
- Emsley R, "The nature of relapse in schizophrenia", BMC Psychiatry, 13, pp.50~ (2013)
- Shimomura Y, "Antipsychotic treatment in the maintenance phase of schizophrenia : an updated systematic review of the guidelines and algorithms", Schizophr Res, 215, pp.8~16 (2020)
- Dans AL, "Users’ guides to the medical literature: XIV. how to decide on the applicability of clinical trial results to your patient", JAMA, 279, pp.545~549 (1998)
- 김지애, "Towards Actualizing the Value Potential of Korea Health Insurance Review and Assessment (HIRA) Data as a Resource for Health Research: Strengths, Limitations, Applications, and Strategies for Optimal Use of HIRA Data", Journal of Korean Medical Science, 32(5), pp.718~728 (2017), 대한의학회
- Gardner DM, "International consensus study of antipsychotic dosing", Am J Psychiatry, 167, pp.686~693 (2010)
- clinical psychiatry, "Kaplan & Sadock’s synopsis of psychiatry: behavioral sciences", pp.2015, Sadock BJ
- Barkhof E, "Interventions to improve adherence to antipsychotic medication in patients with schizophrenia: a review of the past decade", Eur Psychiatry, 27, pp.9~18 (2012)
- Haddad PM, "Nonadherence with antipsychotic medication in schizophrenia : challenges and management strategies", Patient Relat Outcome Meas, 5, pp.43~62 (2014)
- Lieberman JA, "Effectiveness of antipsychotic drugs in patients with chronic schizophrenia", N Engl J Med, 353, pp.1209~1223 (2005)
- Tiihonen J, "20-year nationwide follow-up study on discontinuation of antipsychotic treatment in first-episode schizophrenia", Am J Psychiatry, 175, pp.765~773 (2018)
- Murray RM, "Should psychiatrists be more cautious about the longterm prophylactic use of antipsychotics?", Br J Psychiatry, 209, pp.361~365 (2016)
- Fenton WS, "Determinants of medication compliance in schizophrenia : empirical and clinical findings", Schizophr Bull, 23, pp.637~651 (1997)